Consolidated Entities and Acquisitions - Entasis Therapeutics Holdings, Inc. (Details) $ / shares in Units, $ in Thousands			3 Months Ended
	Jul. 11, 2022 USD ($)	Feb. 17, 2022 USD ($) $ / shares	Mar. 31, 2023 USD ($) Director	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Total debt			$ 453,500		$ 549,704
Remeasurement loss				$ 7,800
Net loss attributable to Innoviva stockholders			34,865	15,773
Net income attributable to noncontrolling interests			$ 0	22,085
Entasis Therapeutics Holdings Inc
Subsidiary or Equity Method Investee [Line Items]
Number of investee's board members which may be designated by the Company | Director			2
Payment towards convertible promissory note	$ 0
Measurement period adjustments for change in value of goodwill			$ 1,200
Measurement period adjustments for change in value of intangible assets			800
Net income attributable to noncontrolling interests		$ 38,500
Net loss				$ (4,500)
Measurement period adjustments for change in value of deferred tax liabilities			$ 400
Entasis Therapeutics Holdings Inc | Consolidated Investees [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity method investment ownership percentage		59.90%
Entasis Therapeutics Holdings Inc | Securities Purchase Agreement | Convertible Promissory Note
Subsidiary or Equity Method Investee [Line Items]
Total debt		$ 15,000
Debt instrument maturity date		Aug. 18, 2022
Debt Instrument, annual interest rate		0.59%
Conversion price (dollars per share) | $ / shares		$ 1.48
Entasis Therapeutics Holdings Inc | Common stock
Subsidiary or Equity Method Investee [Line Items]
Fair value of equity securities		$ 64,500
Entasis Therapeutics Holdings Inc | Warrants
Subsidiary or Equity Method Investee [Line Items]
Fair value of equity securities		$ 31,400